Moving beyond R-CHOP in large B-cell lymphoma
Mené sur 899 patients atteints d'un lymphome diffus à grandes cellules B et à haut risque de récidive (durée médiane de suivi : 35,2 mois), cet essai international de phase III évalue l'efficacité, du point de vue de la survie sans progression, et la toxicité de l'ajout de tafasitamab et de lénalidomide à un traitement de première ligne de type R-CHOP
Outcomes for patients with high-risk large B-cell lymphoma (LBCL), defined by an International Prognostic Index (IPI) score of 3–5, remain unsatisfactory. Despite substantial progress in understanding the biology and molecular heterogeneity of LBCL, R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone or prednisolone) has remained the standard first-line treatment for more than two decades, with durable remissions occurring in approximately 60% of patients.1 Multiple strategies aimed at improving outcomes—including chemotherapy intensification, alternative anti-CD20 antibodies, and targeted agents added to R-CHOP—have generally failed to improve survival.2 In 2022, the POLARIX study showed improved progression-free survival, but not overall survival, with polatuzumab vedotin plus R-CHP (rituximab plus cyclophosphamide, doxorubicin, and prednisone or prednisolone) compared with R-CHOP.3 In The Lancet, Georg Lenz and colleagues4 report the results of the phase 3 frontMIND trial evaluating the anti-CD19 monoclonal antibody tafasitamab and lenalidomide added to R-CHOP (tafa-len-R-CHOP) in patients with newly diagnosed high-risk LBCL.
The Lancet , commentaire, 2026